TRAW Quote, Financials, Valuation and Earnings

Emergent BioSolutions has a net margin of -14868.42% compared to Traws Pharma's net margin of 40.45%. Traws Pharma's return on equity of -124.39% beat Emergent BioSolutions's return on equity of -35.94%.

Traws Pharma has a consensus price target of --, signalling downside risk potential of -25.56%. On the other hand Emergent BioSolutions has an analysts' consensus of $13.50 which suggests that it could grow by 36.64%. Given that Emergent BioSolutions has higher upside potential than Traws Pharma, analysts believe Emergent BioSolutions is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.132, which suggesting that the stock is 13.246% more volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.601, suggesting its more volatile than the S&P 500 by 60.125%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. Traws Pharma's net income of -$8.5M is lower than Emergent BioSolutions's net income of $114.8M. Notably, Traws Pharma's price-to-earnings ratio is -- while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 32.60x versus 0.48x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

Marinus Pharmaceuticals has a net margin of -14868.42% compared to Traws Pharma's net margin of -283.63%. Traws Pharma's return on equity of -124.39% beat Marinus Pharmaceuticals's return on equity of -1150.43%.

Traws Pharma has a consensus price target of --, signalling downside risk potential of -25.56%. On the other hand Marinus Pharmaceuticals has an analysts' consensus of $1.07 which suggests that it could grow by 98.64%. Given that Marinus Pharmaceuticals has higher upside potential than Traws Pharma, analysts believe Marinus Pharmaceuticals is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.132, which suggesting that the stock is 13.246% more volatile than S&P 500. In comparison Marinus Pharmaceuticals has a beta of 1.035, suggesting its more volatile than the S&P 500 by 3.471%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marinus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Marinus Pharmaceuticals pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are smaller than Marinus Pharmaceuticals quarterly revenues of $8.5M. Traws Pharma's net income of -$8.5M is higher than Marinus Pharmaceuticals's net income of -$24.2M. Notably, Traws Pharma's price-to-earnings ratio is -- while Marinus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 32.60x versus 0.97x for Marinus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -14868.42% compared to Traws Pharma's net margin of -49.65%. Traws Pharma's return on equity of -124.39% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Traws Pharma has a consensus price target of --, signalling downside risk potential of -25.56%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Traws Pharma, analysts believe NovaBay Pharmaceuticals is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.132, which suggesting that the stock is 13.246% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Traws Pharma's net income of -$8.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Traws Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 32.60x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Phio Pharmaceuticals has a net margin of -14868.42% compared to Traws Pharma's net margin of --. Traws Pharma's return on equity of -124.39% beat Phio Pharmaceuticals's return on equity of --.

Traws Pharma has a consensus price target of --, signalling downside risk potential of -25.56%. On the other hand Phio Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 2030.18%. Given that Phio Pharmaceuticals has higher upside potential than Traws Pharma, analysts believe Phio Pharmaceuticals is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.132, which suggesting that the stock is 13.246% more volatile than S&P 500. In comparison Phio Pharmaceuticals has a beta of 1.511, suggesting its more volatile than the S&P 500 by 51.085%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Phio Pharmaceuticals pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are larger than Phio Pharmaceuticals quarterly revenues of --. Traws Pharma's net income of -$8.5M is lower than Phio Pharmaceuticals's net income of -$1.5M. Notably, Traws Pharma's price-to-earnings ratio is -- while Phio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 32.60x versus -- for Phio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.